APRE · Insider Trading
Aprea Therapeutics, Inc. Common stock
Every open-market purchase and sale reported by APRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Marc Duey | Director | A | +3,135 | — |
| 2026-06-17 | Richard Peters | Director | A | +3,135 | — |
| 2026-06-17 | Bernd R. Seizinger | Director | A | +3,135 | — |
| 2026-06-17 | Michael Grissinger | Director | A | +3,135 | — |
| 2026-06-17 | Gabriela Gruia | Director | A | +3,135 | — |
| 2026-06-17 | Rifat Pamukcu | Director | A | +3,135 | — |
| 2026-06-17 | John B Henneman III | Director | A | +3,135 | — |
| 2026-06-17 | Jean-Pierre Bizzari | Director | A | +3,135 | — |
| 2026-04-01 | Richard Peters | Director | Buy | +247,830 deriv. | — |
| 2026-04-01 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +61,956 deriv. | — |
| 2026-03-16 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | +10,095 | — |
| 2026-03-16 | Oren Gilad | President/CEO | A | +20,175 | — |
| 2026-02-02 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +5,700 | +$5.07K |
| 2026-02-02 | Oren Gilad | President/CEO | Buy | +28,100 | +$25.01K |
| 2025-12-11 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +5,000 | +$5.83K |
| 2025-12-11 | Oren Gilad | President/CEO | Buy | — | — |
| 2025-12-11 | Marc Duey | Director | Buy | +21,459 | +$25.00K |
| 2025-06-09 | Michael Grissinger | Director | A | +1,045 | — |
| 2025-06-09 | Bernd R. Seizinger | Director | A | +1,045 | — |
| 2025-06-09 | Gabriela Gruia | Director | A | +1,045 | — |
| 2025-06-09 | Jean-Pierre Bizzari | Director | A | +1,045 | — |
| 2025-06-09 | Marc Duey | Director | A | +1,045 | — |
| 2025-06-09 | John B Henneman III | Director | A | +1,045 | — |
| 2025-06-09 | Richard Peters | Director | A | +1,045 | — |
| 2025-06-09 | Rifat Pamukcu | Director | A | +1,045 | — |
| 2025-04-04 | Oren Gilad | President/CEO | Buy | +5,500 | +$10.11K |
| 2025-03-31 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | +3,365 | — |
| 2025-03-31 | Oren Gilad | President/CEO | A | +6,725 | — |
| 2024-10-25 | Marc Duey | Director | Sell | −6,462 | −$29.58K |
| 2024-10-24 | Oren Gilad | President/CEO | Buy | +500 | +$1.96K |
| 2024-10-17 | Marc Duey | Director | Buy | +30,000 | +$131.70K |
| 2024-10-16 | Marc Duey | Director | Buy | +190 | +$490 |
| 2024-10-16 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +50 | +$123 |
| 2024-10-16 | Oren Gilad | President/CEO | Buy | +250 | +$725 |
| 2024-10-15 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +450 | +$1.17K |
| 2024-10-15 | Bernd R. Seizinger | Director | Buy | +10,000 | +$26.80K |
| 2024-10-15 | Oren Gilad | President/CEO | Buy | +1,150 | +$2.97K |
| 2024-06-21 | Richard Peters | Director | A | +1,045 | — |
| 2024-06-21 | Marc Duey | Director | A | +1,045 | — |
| 2024-06-21 | John B Henneman III | Director | A | +1,045 | — |
| 2024-06-21 | Michael Grissinger | Director | A | +1,045 | — |
| 2024-06-21 | Bernd R. Seizinger | Director | A | +1,045 | — |
| 2024-06-21 | Rifat Pamukcu | Director | A | +1,045 | — |
| 2024-05-02 | Nadeem Q. Mirza | Chief Medical Officer | A | +6,730 | — |
| 2024-03-28 | Oren Gilad | President, CEO | A | +6,725 | — |
| 2024-03-28 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | A | +3,365 | — |
| 2024-03-14 | Oren Gilad | President, CEO | Buy | +2,000 | +$14.58K |
| 2024-03-14 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | +1,010 | +$7.36K |
| 2024-03-14 | John B Henneman III | Director | Buy | +6,860 | +$50.01K |
| 2024-03-14 | Bernd R. Seizinger | Director | Buy | +6,860 | +$50.01K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Oren Gilad | President/CEO | 395,095 | $177.40K |
| Marc Duey | Director | 259,892 | $116.69K |
| Bernd R. Seizinger | Director | 48,910 | $21.96K |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 | $19.54K |
| Rifat Pamukcu | Director | 22,689 | $10.19K |
| John B Henneman III | Director | 13,364 | $6.00K |
| Richard Peters | Director | 6,254 | $2.81K |
| Michael Grissinger | Director | 6,024 | $2.70K |
| Jean-Pierre Bizzari | Director | 4,180 | $1.88K |
| Gabriela Gruia | Director | 4,180 | $1.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APRE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.